从Atractylodes macrocephala提取的多糖化合物通过调节肠道微生物群来影响5-HT合成,从而改善小鼠的缺陷便秘
Lei Chen1, Xiangbing Chang1, Chuntao Wu1
1College of Food and Health, Zhejiang Agriculture and Forestry University, Hangzhou, China.
Neurogastroenterology and motility
|July 30, 2024
概括
阿特拉提洛德斯巨头多糖 (PAMK) 通过调节肠道微生物群和血清素通路,有效治疗便秘. 这项研究确定PAMK是改善胃肠道通行和缓解欠缺便秘症状的关键化合物.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 微生物组研究 微生物组研究
背景情况:
- 吸引类巨头科伊兹科伊兹. (A. macrocephala) 是一种用于消化问题的传统草药.
- 在A. macrocephala中,负责促进排便的特定化合物以前未被确定.
研究的目的:
- 为了确定由A. macrocephala负责缓解便秘的生物活性多糖分.
- 阐明作用的潜在机制,包括对肠道微生物群和神经递质通路的影响.
主要方法:
- 使用HPLC,FT-IR和HGPGC的多糖分数 (PAMK) 的表征.
- 在脏缺陷便秘的小鼠模型中评估PAMK疗效,分析便参数,生理指数和短链脂肪酸 (SCFA).
- 研究5-HT受体基因表达,神经递质水平和肠道微生物群组成.
主要成果:
- 在便秘的小鼠中,PAMK显著减少了胃肠道过渡时间,增加了便量和水含量.
- PAMK调节了血清素 (5-HT),SCFA和相关受体 (TPH-1,SERT),以及神经递质 (VIP,SP,MTL) 的水平.
- PAMK的使用改变了关键肠道细菌的丰富性,包括Alistipes, Bacteroides和Odoribacter.
结论:
- 在小鼠中,PAMK有效地改善了脏缺乏性便秘.
- 治疗效果通过调节5-HT通路,相关受体和肠道微生物群组成来调节.
- 这为A. macrocephala在治疗便秘和开发新的治疗策略方面提供了理论基础.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
151
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
151
01:17Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156